The global human growth hormone market size is expected to reach a value of USD 8.5 billion by 2027, registering a CAGR of 8.2% over the forecast period according to this report. Introduction of novel therapies, increasing R&D activities, and rising awareness for the diagnosis and treatment of growth hormone (GH) disorders are expected to drive the market over the forecast period.
Key players operating in the market are involved in extensive R&D activities for the development of novel GH therapies to strengthen their position in the market. For instance, in October 2019, VISEN Pharmaceuticals, a joint venture of Denmark-based Ascendis Pharma A/S, received approval from China National Drug Administration (NMPA) for its new drug (IND) application to start Phase III clinical study of TransCon hGH. Furthermore, two South Korean companies, Genexine Inc. and Handok Inc., are conducting a Phase II clinical trial study on GX-H9, a recombinant human GH for the treatment of adult and pediatric GH deficiency.
Furthermore, increase in the number of regulatory approvals and launch of novel hGH therapies are expected to fuel the market over the forecast period. For instance, in January 2018, Ferring Pharmaceuticals Inc., a Switzerland-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for its new recombinant hGH, Zomacton (somatropin) indicated for the treatment of adult patients with GH deficiency.
Various government and private organizations have been undertaking initiatives and programs to spread awareness about GH deficiency and facilitate timely diagnosis and treatment. Nonprofit organizations such as Human Growth Foundation are engaged in providing research support and spreading awareness about GH deficiency and its treatment. Such initiatives are expected to drive the demand for hGH treatment therapies.
Further key findings from the study suggest:
GH deficiency was the largest application segment in 2019 owing to increase in regulatory approvals and launch of novel therapies
Rising awareness about GH deficiency, coupled with increasing hospital visits for its treatment, is expected to drive the hospital distribution channel segment
North America dominated the human growth hormone market with the largest share in 2019. This is attributed to favorable reimbursement scenario, high awareness, and the presence of major players in the region
Asia Pacific is projected to witness a lucrative CAGR over the forecast period owing to increasing penetration of key players with their new growth hormone therapies
The key players include Novo Nordisk A/S; Pfizer Inc.; Eli Lilly & Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc. (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; and Ipsen.
Key Topics Covered
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Segment Outlook 2.3 Competitive Insights
Chapter 3 Human Growth Hormone (hGH) Market Variables, Trends & Scope 3.1 Market Lineage Outlook 3.1.1 Parent Market Outlook 3.1.2 Ancillary Market Outlook 3.2 Penetration and Growth Prospect Mapping 3.3 Market Dynamics 3.3.1 Market driver analysis 184.108.40.206 Increasing R&D investments 220.127.116.11 Introduction of novel therapies 18.104.22.168 Increasing awareness regarding GH deficiency 22.214.171.124 Robust pipeline 126.96.36.199 Strategic initiatives by key players 3.3.2 Market Restraint Analysis 188.8.131.52 Adverse effects related to hormone therapies 184.108.40.206 Stringent regulatory scenario 220.127.116.11 High treatment cost 3.3.3 Industry challenges 3.4 Human Growth Hormone (hGH) Market Analysis Tools 3.4.1 Industry analysis - Porter's 18.104.22.168 Supplier Power 22.214.171.124 Buyer Power 126.96.36.199 Substitution Threat 188.8.131.52 Threat from new entrants 184.108.40.206 Competitive Rivalry 3.4.2 PESTEL Analysis 220.127.116.11 Political Landscape 18.104.22.168 Environmental Landscape 22.214.171.124 Social landscape 126.96.36.199 Technology landscape 188.8.131.52 Legal Landscape 3.4.3 Major deals and strategic alliances analysis 184.108.40.206 Joint ventures 220.127.116.11 Mergers and acquisitions 18.104.22.168 Licensing and partnership 22.214.171.124 Technology collaborations 126.96.36.199 Strategic Divestments 3.4.4 Market entry strategies
Chapter 4 Human Growth Hormone (hGH) Market - Competitive Analysis 4.1 Recent Developments & Impact Analysis, by Key Market Participants 4.2 Vendor Landscape 4.2.1 List of key distributors and channel partners 4.2.2 Key company market share analysis, 2019 4.3 Public Companies 4.3.1 Company market position analysis 4.3.2 Competitive dashboard analysis 4.4 Private Companies 4.4.1 List of key emerging companies 4.4.2 Regional network map 4.4.3 Company market position analysis
Chapter 5 Human Growth Hormone (hGH) Market: Application Estimates And Trend Analysis 5.1 Definition & Scope 5.2 Application Market Share Analysis, 2019 & 2027 5.3 Segment Dashboard 5.4 Global Human Growth Hormone (hGH) Market, by Application, 2016 to 2027 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 5.5.1 Growth Hormone Deficiency 5.5.2 Turner Syndrome 5.5.3 Idiopathic Short Stature 5.5.4 Prader-Willi Syndrome 5.5.5 Small for Gestational Age 5.5.6 Others
Chapter 6 Human Growth Hormone (hGH) Market: Distribution Channel Estimates And Trend Analysis 6.1 Definition & Scope 6.2 Distribution Channel Market Share Analysis, 2019 & 2027 6.3 Segment Dashboard 6.4 Global Human Growth Hormone (hGH) Market, by Distribution Channel, 2016 to 2027 6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 6.5.1 Hospital Pharmacy 6.5.2 Retail Pharmacy 6.5.3 Online Pharmacy 6.5.4 Specialty Pharmacy
Chapter 7 Human Growth Hormone (hGH) Market: Regional Estimates & Trend Analysis 7.1 Regional Market Snapshot 7.2 Regional Market Share and Leading Players, 2019 7.3 Market Share Analysis by Country, 2019 7.4 SWOT Analysis, by Factor (Political & Legal, Economic and Technological) 7.5 Market Size & Forecasts, and Trend Analysis, 2019 to 2027
Chapter 8 Company Profiles 8.1 Companies Profiled 8.1.1 Novo Nordisk A/S 8.1.2 Pfizer, Inc. 8.1.3 Eli Lilly and Company 8.1.4 Sandoz International GmbH 8.1.5 Merck KGaA 8.1.6 Genentech, Inc. 8.1.7 Ferring B.V. 8.1.8 Ipsen